Abraham Kanate is an Oncology physician affiliated with HonorHealth. OpenAlex indexes 125 publications with 3,143 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Medical Center Dr
Morgantown, WV 26506
Telephone
304-598-4000Provider last certified this registry record 12 Jan 2021.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202534 payments$78,883openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202526 payments$20,190openpaymentsdata.cms.gov ↗
- ADC THERAPEUTICS AMERICA, INC.Program year202512 payments$14,740openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
26.9%Short-acting sulfonamides12.1%Sulfamethoxazole-Trimethoprim100%Part D≥11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor5.9%Valacyclovir100%Part D<11 patients+ 2 more classes in this area
Dermatology
22.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.7%Acyclovir100%Part D≥20 patientsMetabolism & gastrointestinal
15.3%Corticosteroid7.2%Prednisone100%Part D<11 patientsProton pump inhibitor5.4%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation
2024 - Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy
Biology of Blood and Marrow Transplantation
2023 - Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
Leukemia & lymphoma/Leukemia and lymphoma
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Gotfried, MD
HonorHealth
Stuart Triester, MD
HonorHealth
Tania Phillips, MD
HonorHealth
Zain Khalpey, MD, MRCS
HonorHealth
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”